Technical Data
A0859-40H
ADAM 22 (A Disintegrin And Metalloproteinase 22)
Description:
ADAM22 (a disintegrin and metalloprotease 22; also MDC2) is an 85-90kD member of the M12B peptidase family of enzymes. It is expressed on both neurons and astrocytes in cranial regions of the CNS. The human ADAM22 proprecursor is an 881(aa) type I transmembrane protein. It contains a 197aa cleavable proregion (aa26-222) and a 512 aa extracellular domain (ECD) (aa 223-736). The ECD contains a nonfunctional metalloprotease domain (aa239-438), an integrin-binding disintegrin region (aa444-531) and a Cys-rich domain (aa532-678).
Multiple splice variants exist, two of which may involve the ECD. Both show premature truncations. One has a 10 aa substitution for aa 234-906, while a second shows an 11aa substitution for aa332-906. Over aa26-528, human ADAM22 is 90% aa identical to mouse ADAM22.

Applications:
Suitable for use in ELISA, Western Blot, and Immunoprecipitation. Other applications not tested.

Recommended Dilution:
ELISA: 0.5-1.0ug/ml
Western Blot: 0.1-0.2ug/ml
Optimal dilutions to be determined by the researcher.

Storage and Stability:
Lyophilized powder may be stored at 4C for short-term only. Reconstitute to nominal volume by adding sterile 40-50% glycerol and store at -20C. Reconstituted product is stable for 12 months at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
TypeIsotypeCloneGrade
PabIgGAffinity Purified
SizeStorageShippingSourceHost
100ug-20CBlue IceHumanSheep
Concentration:
~0.2mg/ml
Immunogen:
CHO cell-derived, Recognizesombinant human ADAM22; aa26-528; Accession # Q9P0K1, with a Leu78Val substitution.
Purity:
Purified by immunoaffinity chromatography.
Form
Supplied as a lyophilized powder in 0.2um sterile-filtered solution in PBS with 5% trehalose. Reconstitute with 40-50% glycerol, PBS.
Specificity:
Recognizes human ADAM22.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.